130 related articles for article (PubMed ID: 26974336)
21. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.
Carr BI; Pancoska P; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Marco MD; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Semin Oncol; 2014 Jun; 41(3):406-414. PubMed ID: 25023357
[TBL] [Abstract][Full Text] [Related]
22. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
23. The effect of hepatocellular carcinoma bile duct tumor thrombi in liver transplantation.
Kim JM; Kwon CH; Joh JW; Park JB; Gwak MS; Lee JH; Kim GS; Kim SJ; Lee SK
Hepatogastroenterology; 2014 Sep; 61(134):1673-6. PubMed ID: 25436361
[TBL] [Abstract][Full Text] [Related]
24. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
25. Fascin expression in progression and prognosis of hepatocellular carcinoma.
Iguchi T; Aishima S; Umeda K; Sanefuji K; Fujita N; Sugimachi K; Gion T; Taketomi A; Maehara Y; Tsuneyoshi M
J Surg Oncol; 2009 Dec; 100(7):575-9. PubMed ID: 19697358
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations.
Kanematsu M; Semelka RC; Leonardou P; Mastropasqua M; Lee JK
J Magn Reson Imaging; 2003 Aug; 18(2):189-95. PubMed ID: 12884331
[TBL] [Abstract][Full Text] [Related]
27. Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.
Carr BI; Guerra V; Donghia R
J Gastrointest Cancer; 2020 Dec; 51(4):1141-1147. PubMed ID: 32851544
[TBL] [Abstract][Full Text] [Related]
28. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study.
Carr BI; Buch SC; Kondragunta V; Pancoska P; Branch RA
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1259-66. PubMed ID: 18699979
[TBL] [Abstract][Full Text] [Related]
29. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
30. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival.
Kiriyama S; Uchiyama K; Ueno M; Ozawa S; Hayami S; Tani M; Yamaue H
Ann Surg; 2011 Dec; 254(6):984-91. PubMed ID: 21606837
[TBL] [Abstract][Full Text] [Related]
31. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
[TBL] [Abstract][Full Text] [Related]
32. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
Stuart KE; Anand AJ; Jenkins RL
Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
[TBL] [Abstract][Full Text] [Related]
34. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
36. Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors.
Gao B; Yang FM; Yu ZT; Li R; Xie F; Chen J; Luo HJ; Zhang JC
Int J Clin Exp Pathol; 2015; 8(6):6995-7001. PubMed ID: 26261589
[TBL] [Abstract][Full Text] [Related]
37. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.
Hepatology; 1998 Sep; 28(3):751-5. PubMed ID: 9731568
[TBL] [Abstract][Full Text] [Related]
38. Elevated alpha-fetoprotein levels in hepatocellular carcinoma.
Yao FY
Am J Gastroenterol; 1999 Nov; 94(11):3387. PubMed ID: 10566766
[No Abstract] [Full Text] [Related]
39. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients.
Abdelgawad IA
J Clin Pathol; 2015 Feb; 68(2):154-60. PubMed ID: 25430496
[TBL] [Abstract][Full Text] [Related]
40. [Tumor markers of hepatocellular carcinoma with special reference to diagnostic efficacy of combination of these markers and relation to its stages].
Sawabu N; Wakabayashi T; Ozaki K; Toya D; Yoneshima M
Gan No Rinsho; 1983 May; 29(6):672-7. PubMed ID: 6192267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
